**Core tip:** According to the current treatment guidelines, patients with liver-confined hepatocellular carcinoma and Eastern Cooperative Oncology Group score of 1 alone should be classified as advanced stage and treated with systemic therapy. However, transarterial chemoembolization is commonly used for this group of patients in clinical practice. The current study retrospectively included 792 eligible patients from 24 Chinese tertiary hospitals and found transarterial chemoembolization was effective for hepatocellular carcinoma patients with Eastern Cooperative Oncology Group score of 1 alone, and the "six-and-twelve criteria", defined as the algebraic sum of tumor size (cm) and tumor number, might help the risk stratification and survival prediction.

INTRODUCTION
============

According to the Barcelona Clinic Liver Cancer (BCLC) staging system and treatment guidelines, transarterial chemoembolization (TACE) is currently the only recommended therapy for patients with hepatocellular carcinoma (HCC) of intermediate stage\[[@B1]-[@B3]\]. However, the application of TACE is beyond such recommen-dations in clinical practice especially for advanced diseases\[[@B4]-[@B6]\]. In the BCLC system, advanced HCC is characteristic of macrovascular invasion (MVI), extrahepatic spread (EHS) and tumor-related symptoms based on Eastern Cooperative Oncology Group (ECOG) scoring. With at least one of these features, except preserved liver function, the patients should be stratified into advanced stage\[[@B1],[@B7]\]. However, the population is of high heterogeneity because of such definitions.

Previously, it has been demonstrated that advanced HCC patients with ECOG 1 alone are different from those with MVI and/or EHS\[[@B8]\]. The presence of mild tumor-related symptoms (ECOG 1) should not be considered as an independent feature of advanced HCC\[[@B9]\]. Therefore, it is unclear whether patients with liver-confined HCC and mild symptoms ought to be included in intermediate or advanced stage. This group of patients is considered to be substage B4 according to the substratification of BCLC, which is different from its original definitions\[[@B10]\]. The Hong Kong Liver Cancer system regards patients with asymptomatic and mild symptomatic HCC to be the same and recommends that patients with ECOG 1 receive TACE\[[@B11]\]. Similarly, advanced HCC patients with ECOG 1 have been recruited for evaluation of TACE in several observational studies and randomized controlled trials\[[@B12]-[@B15]\].

Consequently, whether advanced HCC patients with ECOG 1 alone should be classified into the intermediate stage and recommended for TACE remains inconclusive. This study focused on such patients and investigated the treatment outcomes of TACE and the independent predictive factors of survival and proposed a special prognostic score for patient stratification and individual prediction.

MATERIALS AND METHODS
=====================

Study population
----------------

A total of 3819 consecutive patients from 24 tertiary Chinese centers treated with TACE between January 2010 and May 2016 were retrospectively selected. HCC was diagnosed by histological or imaging evaluation according to the American Association for the Study of Liver Diseases/European Association for the Study of the Liver guidelines and was initially treated with TACE without any prior management\[[@B2],[@B3]\]. Patients meeting one of the following criteria were excluded: (1) Presence of MVI and/or EHS; (2) Child--Pugh score \> 7 or decompensation; (3) ECOG performance status score 0; (4) Tumor rupture; (5) Additional systemic treatment; (6) Other malignancies; and (7) Absence of image information. Finally, 792 advanced HCC patients with exclusive ECOG 1 were included (Figure [1](#F1){ref-type="fig"}). Written informed consent was obtained from all patients before treatment initiation. The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki and was approved by the Institutional Review Boards of participating centers.

![Flow chart for patient eligibility. HCC: Hepatocellular carcinoma; ECOG: Eastern Cooperative Oncology Group.](WJG-26-1805-g001){#F1}

TACE treatment and follow-up
----------------------------

All participating centers had specific expertise in the management of HCC and the practice of TACE. Treatment decisions were made at the discretion of the multidisciplinary liver tumor boards in each institution. Before TACE, digital subtraction angiography of the hepatic artery was performed to assess the vascular anatomy and tumor vascularity. During TACE, a vascular catheter was inserted selectively or super-selectively into the tumor-feeding artery followed by injection containing a mixture of doxorubicin (10-50 mg), cisplatin (10-110 mg), epirubicin (10-50 mg) or oxaliplatin (100-200 mg), which was selected according to the practice of each center and then embolization using gelatin sponge or polyvinyl alcohol foam particles. "On-demand" TACE procedures, based on laboratory assessment and radiological evaluation performed by contrast-enhanced computed tomography or magnetic resonance imaging at an interval of 6-12 wk, were scheduled after the procedure. However, in clinical practice, the intensity of follow-up depended on individuals' baseline characteristics and responses to the last treatment, *i.e*. on demand. Thus, not all patients strictly stuck to this imaging follow-up schedule.

Statistical analysis
--------------------

Categorical variables were described as frequencies and percentages; continuous data were shown as mean values with standard deviation or median with interquartile range (IQR). Overall survival (OS) was defined as the time interval between initial TACE and all-cause death or the last clinical follow-up and was estimated using Kaplan--Meier curves and compared by the log-rank test. Patients who survived at last follow-up date (December 15, 2017) or who were lost to follow-up were censored. To disclose the prognostic factors, univariate analyses for OS were applied to the cohort, then significant variables (*P* \< 0.05) were entered into three Cox multivariate regression analysis models. Variables related to liver function \[Child--Pugh class, albumin--bilirubin (ALBI) grade and total bilirubin (TBIL)\] were separately included in the multivariate model 1, model 2 and model 3 with stepwise manners for analyses. According to the different accompanying hazard ratio (HR) estimated for each model, a linear predictor was calculated by adding each independent prognostic factor assigned its own weight. Comparison of the performance and discriminating abilities of the proposed models were measured by C index (measure of goodness of fit for binary outcomes in a logistic regression model), likelihood ratio *χ*^2^, area under time-dependent receiving operator characteristic curve, and R^2^. Statistical analysis was conducted using SPSS version 17.0 (SPSS Inc., Chicago, IL, United States) and R version 3.3.1 (R Foundation for Statistical Computing, Vienna, Austria).

RESULTS
=======

Patient characteristics
-----------------------

Baseline characteristics for the cohort consisting of 792 eligible patients are shown in Table [1](#T1){ref-type="table"}. The mean age was 56.4 years, and hepatitis B virus infection was the main etiology of HCC. Liver function in 742 (93.7%) patients was classed as Child--Pugh class A while the remaining 50 (6.3%) were class B (only Child--Pugh score 7). At the same time, 323 (40.8%) patients were graded as ALBI 1, 458 (57.8%) as ALBI 2 and 11 (1.4%) as ALBI 3. The median tumor size was 8.2 cm with an average of 8.6 cm. Median tumor number was 1 (IQR 1-3). During follow-up, the median number of TACE sessions for each patient reached 2 (IQR 1-4).

###### 

Baseline characteristic for the cohort, *n* = 792

  **Characteristics**                          **Values**
  -------------------------------------------- --------------------------------
  Age at start, yr, mean ± SD                  56.4 ± 11.6
  Gender, men/women, *n* (%)                   663 (83.7)/129 (16.3)
  Etiology, HBV/non-HBV, *n* (%)               681 (86.0)/111 (14.0)
  Child-Pugh class, A/B, *n* (%)               742 (93.7)/50 (6.3)
  ALBI grade, 1/2/3, *n* (%)                   323 (40.8)/458 (57.8)/11 (1.4)
  Tumor size, cm, mean ± SD/median (IQR)       8.6 ± 4.1/8.2 (5.2-11.5)
  Tumor number, mean ± SD/median (IQR)         2.4 ± 2.2/1 (1-3)
  AFP, ≤ 400/\> 400 ng/mL/NA, *n* (%)          431 (54.4)/337 (42.6)/24 (3.0)
  White blood cell, 10^9^/L, mean ± SD         5.8 ± 2.6
  Red blood cell, 10^6^/L, mean ± SD           4.4 ± 0.7
  Platelets, 10^9^/L, mean ± SD                158.4 ± 88.9
  International normalized ratio, mean ± SD    1.08 ± 0.12
  Alanine aminotransferase, U/L, mean ± SD     53.0 ± 47.3
  Aspartate aminotransferase, U/L, mean ± SD   67.5 ± 59.6
  Albumin, g/L, mean ± SD                      38.7 ± 7.0
  Total bilirubin, μmol/L, mean ± SD           18.1 ± 8.5
  Urea nitrogen, mmol/L, mean ± SD             5.5 ± 3.1
  Serum creatinine, μmol/L, mean ± SD          71.9 ± 20.7
  Sessions of TACE, mean ± SD/ median (IQR)    2.9 ± 2.0/2 (1-4)

SD: Standard deviation; IQR: Interquartile range; HBV: Hepatitis B virus; ALBI: Albumin-bilirubin; AFP: Alpha-fetoprotein; TACE: Transarterial chemoembolization.

OS
--

With a median follow-up of 14.9 mo (IQR 7.0-27.1), 97 (12.2%) patients were lost to follow-up, 500 (63.1%) died and 195 (24.6%) survived. Median OS was 18.9 mo (95%CI: 16.9-21.0) for the whole cohort (Figure [2A](#F2){ref-type="fig"}). According to Child--Pugh classification, patients with class A had a median OS of 19.6 mo, which was better than 13.5 mo for class B (log-rank *P* = 0.046) (Figure [2B](#F2){ref-type="fig"}). As for ALBI grade, the median OS for patients with grade 1 was 20.5 mo, which was significantly longer than the 17.7 mo and 5.8 mo for patients with grade 2 and 3, respectively (log-rank *P* = 0.001) (Figure [2C](#F2){ref-type="fig"}). The patients with lower α-fetoprotein (AFP; no more than 400 ng/mL) had a median OS of 22.7 mo, while those with higher AFP value had a shorter median OS of 13.5 mo (log-rank *P* \< 0.001) (Figure [2D](#F2){ref-type="fig"}).

![Kaplan--Meier curves for survival analysis and comparisons. A: Survival analysis of the whole cohort; B: Comparisons among patients with different Child-Pugh class; C: Comparisons among patients with different albumin-bilirubin grade; D: Comparisons among patients with different alpha-fetoprotein level. ALBI: Albumin-bilirubin; AFP: Alpha-fetoprotein.](WJG-26-1805-g002){#F2}

Independent prognostic factors
------------------------------

Univariate analyses for OS are shown in Table [2](#T2){ref-type="table"}, suggesting that tumor size, tumor number, Child--Pugh class, ALBI grade, AFP level, white blood cells, platelets, aspartate aminotransferase and TBIL were all associated with survival (*P* \< 0.05). Including all these predictive factors except ALBI grade and TBIL, the multivariate model 1 demonstrated that tumor size (HR = 1.10, 95%CI: 1.08-1.12, *P* \< 0.001), tumor number (HR = 1.10, 95%CI: 1.07-1.14, *P* \< 0.001) and AFP level (HR = 1.31, 95%CI: 1.09-1.98, *P* = 0.047) were independent prognostic factors of OS (Table [3](#T3){ref-type="table"}). However, the multivariate model 2 included the significant factor in univariate analysis except for Child--Pugh class and TBIL and found that tumor size (HR = 1.10, 95%CI: 1.08-1.12, *P* \< 0.001), tumor number (HR = 1.10, 95%CI: 1.06-1.64, *P* \< 0.001), AFP level (HR = 1.36, 95%CI: 1.13-1.63, *P* = 0.001) and ALBI grade (HR = 1.44, 95%CI: 1.20-1.72, *P* \< 0.001) were associated with OS. Finally, the multivariate model 3 revealed that tumor size (HR = 1.10, 95%CI: 1.07-1.12, *P* \< 0.001), tumor number (HR = 1.11, 95%CI: 1.07-1.15, *P* \< 0.001), AFP level (HR = 1.28, 95%CI: 1.06-1.53, *P* = 0.010) and TBIL (HR = 1.01, 95%CI: 1.00-1.02, *P* = 0.025) predicted OS independently after including the predictors of univariate analysis, except for Child--Pugh class and ALBI grade.

###### 

Univariate analyses for overall survival

  **Characteristics**                               **HR (95%CI)**     ***P* value**
  ------------------------------------------------- ------------------ ---------------
  Gender, male (Ref: Female)                        0.84 (0.66-1.08)   0.167
  Age, per yr increase                              1.00 (0.99-1.01)   0.429
  Etiology Others (Ref: HBV)                        0.79 (0.61-1.04)   0.092
  Tumor size, per 1 cm increase                     1.10 (1.08-1.13)   \< 0.001
  Tumor number, per 1 lesion increase               1.11 (1.07-1.15)   \< 0.001
  Child-Pugh class B (Ref: A)                       1.41 (1.00-1.98)   0.047
  ALBI grade 2 (Ref: 1)                             1.35 (1.14-1.61)   0.001
  AFP \> 400 ng/mL (Ref: ≤ 400 ng/mL)               1.51 (1.26-1.81)   \< 0.001
  White blood cell, per 1 10^9^/L increase          1.07 (1.04-1.10)   \< 0.001
  Red blood cell, per 1 10^6^/L increase            0.87 (0.74-1.03)   0.098
  Platelets, per 1 10^9^/L increase                 1.00 (1.00-1.00)   \< 0.001
  International normalized ratio, per 1% increase   0.96 (0.46-1.99)   0.903
  Alanine aminotransferase, per 1 U/L increase      1.00 (1.00-1.00)   0.606
  Aspartate aminotransferase, per 1 U/L increase    1.00 (1.00-1.01)   0.011
  Total bilirubin, per 1 μmol/L increase            1.02 (1.01-1.03)   0.004
  Albumin, per 1 g/L increase                       0.99 (0.98-1.01)   0.200
  ALBI score, per 1 score increase                  1.18 (0.99-1.40)   0.062
  Blood urea nitrogen, per 1 mmol/L increase        0.98 (0.94-1.02)   \< 0.315
  Creatinine, per 1 μmol/L increase                 1.01 (1.00-1.01)   0.881

HR: Hazard ratio; Ref: Reference; HBV: Hepatitis B virus; AFP: Alpha-fetoprotein; ALBI: Albumin-bilirubin.

###### 

Multivariate analyses for overall survival

  **Characteristics**                      **Model 1**        **Model 2**   **Model 3**                                      
  ---------------------------------------- ------------------ ------------- ------------------ ---------- ------------------ ----------
  Tumor size, per 1 cm increase            1.10 (1.08-1.12)   \< 0.001      1.10 (1.08-1.12)   \< 0.001   1.10 (1.07-1.12)   \< 0.001
  Tumor number, per 1 lesion increase      1.10 (1.07-1.14)   \< 0.001      1.10 (1.06-1.64)   \< 0.001   1.11 (1.07-1.15)   \< 0.001
  AFP \> 400 ng/mL (Ref: ≤ 400 ng/mL)      1.31 (1.09-1.98)   0.047         1.36 (1.13-1.63)   0.001      1.28 (1.06-1.53)   0.010
  Child-Pugh class B (Ref: A)                                                                                                
  ALBI grade 2 (Ref: 1)                                                     1.44 (1.20-1.72)   \< 0.001                      
  Total bilirubin, per 1 μmol/L increase                                                                  1.01 (1.00-1.02)   0.025

Significant characteristics (*P* \< 0.05) in univariate analysis were included in cox regression models, and these variables related to liver function (Child-Pugh grade, ALBI grade and total bilirubin) were respectively included in the multivariate Model 1, Model 2 and Model 3. HR: Hazard ratio; Ref: Reference; AFP: Alpha-fetoprotein; ALBI: Albumin-bilirubin.

Development of the prognostic model
-----------------------------------

According to the three multivariate models, tumor size, tumor number and AFP level were reliable prognostic factors of OS, but the factors related to liver function performed differently in these models (Table [3](#T3){ref-type="table"}). The regression coefficients for tumor size, tumor number and AFP level were 0.093, 0.097 and 0.266, respectively in model 1. In model 2, the regression coefficients for tumor size, tumor number, AFP level and ALBI grade were 0.095, 0.097, 0.304 and 0.361, respectively. In model 3, the regression coefficients for tumor size, tumor number, AFP level and TBIL were 0.092, 0.102, 0.243 and 0.012, respectively. For ease of use, 1 divided by the regression coefficients for tumor size was the constant of each formula. Then, the regression coefficients for other predictors were respectively multiplied by the constant to achieve their coefficients in the formulas. Additionally, considering the robust prognostic value of tumor size and tumor number, our previously proposed six-and-twelve (6&12) criteria was also evaluated\[[@B16]\]. This prognostic model was "linear predictor = largest tumor diameter (cm) + tumor number" and could divide patients enrolled into three risk stratifications with the cut-off values "6" and "12", which may provide an easy-to-use tool (a nomogram developed based on statistical results) for classification and individual survival prediction. Finally, the formulas as shown in Table [4](#T4){ref-type="table"} were used for calculating the linear predictor of each proposed model. Comparisons among them demonstrated that model 3 and 6&12 criteria model exhibited an advantage over models 1 and 2 in predicting performance and discriminating ability, while no significant differences were seen between model 3 and the 6&12 criteria model (Figure [3](#F3){ref-type="fig"}). It can be seen from above that the 6&12 criteria model was still the first choice as an easy-to-use clinical tool. In particular, the 6&12 criteria could predict OS regardless of gender, age, AFP level, Child--Pugh score, ALBI grade and etiology (Figure [4](#F4){ref-type="fig"}).

![Time-dependent receiver operating characteristic analysis for the proposed prognostic models and six-and-twelve criteria. AUROC: Area under receiver operating characteristic. 6&12: Six-and-twelve.](WJG-26-1805-g003){#F3}

###### 

Comparison of the performance and discriminating abilities of the proposed models and six-and-twelve criteria

  **Prognostic models**                         **AUROC (95%CI)**   **LR *χ*^2^**      **df**             **C-index (95%CI)**   **R^2^**                      
  --------------------------------------------- ------------------- ------------------ ------------------ --------------------- ---------- ------------------ -------
  Model 1                                       0.72 (0.68-0.76)    0.69 (0.65-0.74)   0.66 (0.60-0.71)   98.4                  3          0.65 (0.63-0.68)   0.117
  LP = TS + TN + 2.9 × AFP                                                                                                                                    
  Model 2                                       0.72 (0.68-0.76)    0.69 (0.56-0.73)   0.67 (0.61-0.72)   101.4                 4          0.66 (0.64-0.69)   0.120
  LP = TS + TN + 3.2 × AFP + 3.8 × ALBI                                                                                                                       
  Model 3                                       0.74 (0.71-0.78)    0.72 (0.68-0.76)   0.68 (0.63-0.74)   124.3                 4          0.67 (0.65-0.70)   0.149
  LP = TS + 1.1 × TN + 2.7 × AFP + 0.1 × TBIL                                                                                                                 
  Six-and-twelve criteria                       0.74 (0.70-0.77)    0.71 (0.67-0.75)   0.68 (0.63-0.74)   114.3                 2          0.67 (0.64-0.69)   0.134
  LP = TS + TN                                                                                                                                                

AUROC: Area under receiver operating characteristic curve; LR: Likelihood ratio; LP: Linear predictor; TS: Tumor size; TN: Tumor number; ALBI: Albumin-bilirubin grade; AFP: Alpha-fetoprotein; TBIL: Total bilirubin.

![Subgroup analysis for evaluating the prognostic values of six-and-twelve criteria. HR: Hazard ratio; CI: Confidence interval; ALBI: Albumin-bilirubin; AFP: Alpha-fetoprotein; HBV: Hepatitis B virus. 6&12: Six-and-twelve.](WJG-26-1805-g004){#F4}

Individual survival prediction and risk stratification
------------------------------------------------------

Based on these findings, the relationship between tumor size and tumor number, as well as 3-year survival probability was depicted in a contour plot (Figure [5A](#F5){ref-type="fig"}). In addition, a nomogram was created for individual survival prediction of patients; the 1-year, 2-year and 3-year survival rates of individual patients can be predicted by the sum of tumor size and number (6&12 criteria) prior to TACE (Figure [5B](#F5){ref-type="fig"}). For risk stratification of patients, the cut-off values of the 6&12 criteria were used for the patient classification (Figure [5C](#F5){ref-type="fig"}). For patients with low tumor burden, the median OS reached 39.8 mo (95%CI: 23.9-55.7), which was better than that of 21.1 mo (95%CI: 18.4-23.8) in moderate tumor burden and 9.8 mo (95%CI: 8.3-11.3) in high tumor burden (*P* \< 0.001).

![Six-and-twelve criteria tools for clinical use in advanced hepatocellular carcinoma patients with Eastern Cooperative Oncology Group performance status score 1 alone. A: Survival prediction for six-and-twelve (6&12) criteria using contour plot of 3-year survival probability; B: Nomogram based on the cut-off value of 6&12 criteria; C: Patient stratification based on the cut-off value of 6&12 criteria.](WJG-26-1805-g005){#F5}

DISCUSSION
==========

In this nationwide multicenter study, we retrospectively explored the treatment outcomes of TACE in advanced HCC patients with ECOG 1 alone and investigated the prognostic factors for OS. Overall, the median OS for all patients reached 18.9 mo. Remarkably, it was demonstrated that tumor size and number were robust prognostic factors of OS, based on which the 6&12 criteria showed consistent discriminatory ability. In addition, the 6&12 criteria could stratify these patients into three subgroups with significantly different OS after TACE.

According to the current treatment guidelines, TACE is recommended for patients with intermediate HCC\[[@B2],[@B3]\]. However, many advanced HCC patients receive TACE in clinical practice especially those with tumors confined to the liver\[[@B4],[@B17]\]. The median OS of 18.9 mo in our study was consistent with previous reports in real-world conditions with a median OS of 19.2 mo in which the patients with unresectable early or intermediate HCC were included\[[@B18]\]. Therefore, the treatment outcomes of the current study indicated that those advanced HCC patients with ECOG 1 would be suitable for TACE and could be included in the intermediate stage. In the Hong Kong Liver Cancer staging system, ECOG 1 was regarded the same as ECOG 0, and those patients should be treated with TACE or curative therapies\[[@B11]\]. In the BCLC system, inclusion of patients with ECOG 1 but without MVI/EHS in BCLC B stage improved the discrimination of the staging system\[[@B9]\]. However, according to the substratification of BCLC B stage, advanced HCC patients with ECOG 1 were recognized as B4 stage, who had a worse prognosis compared with others in B stage\[[@B19],[@B20]\]. In addition, best supportive care was initially recommended to them rather than TACE and even systemic therapies\[[@B10]\]. Consequently, the risk stratification and treatment arrangement of these patients remain controversial.

As a highly complex technical procedure, TACE is operator-dependent and heterogeneity exists in the techniques and agents used, which might explain variations in outcomes in patients with HCC\[[@B21]\]. However, there is no consensus on the optimal chemotherapeutic agent to use in TACE. Worldwide, the most popular anticancer drug injected is doxorubicin\[[@B22]\]. In addition, a recent randomized controlled trial comparing TACE with transarterial embolization found no diﬀerences in terms of tumor response and OS, which questioned the effects of chemotherapy agents\[[@B12]\]. Considering these points, using the mixture of doxorubicin, cisplatin, epirubicin or oxaliplatin might have little effect on our current analysis. Although TACE was the most commonly used treatment for patients with unresectable HCC, sorafenib was the recommended systemic therapy for advanced disease and has been effective worldwide\[[@B4],[@B6],[@B23],[@B24]\]. Furthermore, combining TACE and sorafenib might be a "good marriage" for unresectable HCC\[[@B25],[@B26]\]. In addition, systemic chemotherapy with doxorubicin or FOLFOX did not demonstrate survival benefits\[[@B27],[@B28]\]. Major emphasis has been focused on the efficacy of transarterial radioembolization. In cohort studies, transarterial radioembolization showed tumor response rates between 40% and 90%, and survival was comparable to that obtained with TACE and sorafenib\[[@B29],[@B30]\]. However, randomized controlled trials failed to demonstrate a survival benefit from transarterial radioembolization compared with sorafenib\[[@B31]\]. Recently, lenvatinib was found to be non-inferior to sorafenib, offering another treatment option for patients with advanced HCC\[[@B32]\]; however, large multicenter real-world studies are highly needed.

In the current study, we performed in-depth investigation into this population and stratified the patients according to tumor burden. For patients with low tumor burden based on 6&12 criteria, the median OS was 39.8 mo, which was comparable to that of the patients with intermediate HCC\[[@B16]\]. It might be inferred that this group of patients would be suitable for TACE alone and should be preferably regarded as intermediate stage. As for patients with high tumor burden, they had a median OS of 9.8 mo. Compared with the advanced HCC patients receiving systemic therapy, TACE might be unacceptable\[[@B32]-[@B35]\]. Because of the potential adverse effect of TACE on liver function, HCC tumors \> 10 cm are commonly considered to be a contraindication for TACE\[[@B21]\]. In addition, the patients with moderate tumor burden had a median OS of 21.1 mo. For them, combining TACE with systemic treatment might make a difference. Consequently, according to the patient stratification with 6&12 criteria, these findings might not only facilitate the outcome prediction but also provide a reference for stratified staging of these patients and help the decision-making.

The current study, for the first time, focused on advanced HCC patients with ECOG 1 alone, investigated the treatment outcomes of TACE and proposed a specific prognostic system for patient stratification and survival prediction, which could better guide treatment selection in this controversial population. There were several limitations to this retrospective cohort study. Firstly, the potential patient selection bias was unavoidable for this retrospective observational study. Nevertheless, this bias might be reduced by including a large cohort of consecutive patients. Secondly, TACE is not recommended by the guidelines for treatment of advanced HCC\[[@B2],[@B3]\]. Although systemic therapies are recommended for advanced HCC, they mainly refer to patients with MVI/EHS, and it is inconclusive whether advanced HCC patients with ECOG 1 alone should be placed in intermediate or advanced stages. Finally, with the absence of external validation, the generalization and extrapolation of the current findings should be made with caution. However, the results of this study came from a multicenter cohort from 24 tertiary Chinese hospitals, and subgroup analysis demonstrated the reliable and consistent predictive factors of the proposed 6&12 criteria.

In summary, our study demonstrated that TACE was safe and effective for advanced HCC patients with ECOG 1 alone; tumor size and tumor number, rather than the liver function or AFP level, were robust prognostic factors of OS after TACE. Based on these findings, the 6&12 criteria could predict prognosis regardless of baseline characteristics. Future studies focusing on these patients with other treatment modalities are still required.

ARTICLE HIGHLIGHTS
==================

Research background
-------------------

According to the international guidelines, the advanced stage of hepatocellular carcinoma (HCC) covers patients with liver-confined HCC and Eastern Cooperative Oncology Group (ECOG) performance status score 1. Despite the recommended standard treatment of systemic therapy, these patients are frequently treated with transarterial chemoembolization (TACE) in real world clinical practice.

Research motivation
-------------------

Previously, some studies demonstrated different prognoses between advanced HCC patients with ECOG 1 alone and others with macrovascular invasion or extrahepatic spread. Whether such patients should be classified into intermediate stage and treated with TACE still remains unknown. Specific studies focusing on the survival is necessary.

Research objectives
-------------------

This nationwide multicenter study aimed to investigate treatment outcomes of TACE in advanced HCC patients with ECOG 1 alone and propose a specific prognostic model.

Research methods
----------------

Several potential prognostic models were developed based on univariate analyses and multivariate Cox regression analyses. Then, the discriminatory ability of them were compared with six-and-twelve (6&12) criteria, defined as the algebraic sum of tumor size (cm) and tumor number, in 792 patients and their subgroups. Contour plot of 3-year survival probability and nomogram were used to illustrate the individual survival prediction of 6&12 criteria in advanced HCC patients with ECOG 1 alone receiving TACE.

Research results
----------------

The analyses showed that tumor size, tumor number, α-fetoprotein level, albumin--bilirubin grade and total bilirubin were prognostic factors of overall survival (OS). In the comparisons between 6&12 criteria and three newly proposed models containing different prognostic factors, the 6&12 criteria retained the highest predictive ability and was the easiest to use. Additionally, the 6&12 criteria was correlated with OS in various subgroups of patients and could stratify patients into three risk strata with cut-off values "6" and "12".

Research conclusions
--------------------

The results from this study suggest that TACE is effective for advanced HCC patients with ECOG 1 alone. The 6&12 criteria including two robust prognostic factors (tumor size and tumor number) of OS could be applied in risk stratification and individual prediction, which might help with clinical decision-making.

Research perspectives
---------------------

This study explored the applicability of TACE for advanced HCC patients with ECOG 1 alone and proposed a predictive score for OS. Also, other possible treatment approaches used in clinical practice exist. Future studies should investigate the outcomes of different treatments and compare them with TACE to further manage these patients with the most appropriate therapy.
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